Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study

Pulmonology. 2021 Mar-Apr;27(2):175-177. doi: 10.1016/j.pulmoe.2020.08.007. Epub 2020 Sep 21.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • ErbB Receptors* / genetics
  • Erlotinib Hydrochloride / therapeutic use
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Mutation
  • Portugal / epidemiology

Substances

  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors